Plasma Endothelin Levels in Hypertension and Chronic Renal Failure

Masayoshi Shichiri, Yukio Hirata, Kenji Ando, Toshiaki Emori, Kazuki Ohta, Shigeaki Kimoto, Mitsuo Ogura, Atsushi Inoue, and Fumiaki Marumo

Endothelin-1 is a novel endothelium-derived vasoconstrictive peptide. Using a highly specific and sensitive radioimmunoassay for endothelin-1, plasma levels of immunoreactive endothelin-1 were measured in 32 research subjects with normal renal function (21 normal subjects and 11 patients with essential hypertension), 24 patients with nondialyzed chronic renal failure, and 51 patients undergoing maintenance hemodialysis. Although there was no significant difference in plasma immunoreactive endothelin-1 levels among the three groups, patients with essential hypertension had significantly higher plasma endothelin-1 levels than normal subjects (2.29±1.09 vs. 1.41±0.50 pg/ml, p<0.025). When nondialyzed and hemodialyzed patients were divided into hypertensive and normotensive groups, the nondialyzed hypertensive group (n=17) had higher plasma endothelin-1 levels than the comparable normotensive group (n=7) (3.08±3.43 vs. 0.73±0.34 pg/ml, p<0.05), and the hemodialyzed hypertensive group (n=18) had higher plasma endothelin-1 levels than the comparable normotensive group (n=33) (2.66±1.92 vs. 1.35±0.73 pg/ml, p<0.005). Plasma atrial natriuretic factor, arginine vasopres- sin, renin activity, and aldosterone concentration did not show significant differences between hypertensive and normotensive individuals or a correlation with plasma endothelin-1 levels. These data suggest that circulating endothelin-1 may be partly involved in the development or maintenance of hypertension in humans. (Hypertension 1990;15:493-496)
Measurements of Immunoreactive Endothelin and Other Hormones

Blood samples (7 ml) from normal subjects, patients with essential hypertension, and those with nondialyzed renal failure were withdrawn, while the subject or patient was in a sitting position, from the antecubital vein into K₂-EDTA tubes placed on ice. For hemodialysis patients, blood sampling was done while they were in a recumbent position at the start of hemodialysis. Plasma was immediately separated and stored at −40°C until assayed. Plasma ET-LI levels were determined by RIA as described previously. In short, a 2 ml aliquot of plasma was acidified with trifluoroacetic acid (TFA) and applied to a Spe-C cartridge (J.T. Baker Inc., Phillipsburg, New Jersey), which had been prewashed sequentially with methanol, distilled water, and 0.09% TFA. The materials adsorbed to the cartridge were eluted with 60% acetonitrile/0.09% TFA. The minimum detectable quantity of ET-1 in RIA was 0.5 pg/tube, and the 50% intercept was 15 pg/tube. The antibody mainly recognizes the C-terminal Trp²¹ residue of ET-1; it cross-reacted fully with ET-1, ET-2, and ET-3, although it did not show any cross-reactivities with big porcine ET-1 (1–39), big human ET-1 (1–38), or C-terminal fragment (22–39) of big porcine ET-1. Plasma concentrations of human atrial natriuretic factor were determined by RIA as described previously. Plasma arginine vasopressin, plasma renin activity, and plasma aldosterone concentration were determined by their specific RIAs.

Statistical Analysis

Results were expressed as mean±SD. Analyses were performed using Wilcoxon's test for nonpaired data. Statistical significance was accepted for p<0.05.

Results

Clinical characteristics of each group are shown in Table 1. There was no statistical difference in plasma ET-LI levels among the following three groups: 32 subjects with normal renal function (21 normal subjects plus 11 patients with essential hypertension, 1.72±0.84 pg/ml), 24 patients with nondialyzed renal failure (2.46±3.12 pg/ml), and 51 patients undergoing chronic hemodialysis (1.81±1.41 pg/ml). Plasma ET-LI levels in the 21 normal subjects were 1.41±0.50 pg/ml. Eleven patients with essential hypertension showed higher plasma ET-LI levels (2.29±1.09 pg/ml) than the normal subjects (p<0.025). When both nondialyzed and hemodialyzed renal failure groups were further divided into hypertensive and normotensive subgroups, the hypertensive groups showed significantly higher plasma ET-LI levels than the comparable normotensive groups (nondialyzed 3.08±3.43 pg/ml [n=17], p=0.05; hemodialyzed 2.66±1.92 pg/ml [n=18] vs. 1.35±0.73 pg/ml [n=33], p<0.005) (Figure 1). There were no statistical differences in atrial natriuretic factor, arginine vasopressin, plasma renin activity, and plasma aldosterone concentration between normal subjects and patients with essential hypertension, between the hypertensive and the normotensive with nondialyzed renal failure groups, or between the two groups on hemodialysis (Table 1). Plasma ET-LI levels did not show any correlations with atrial natriuretic factor (r=−0.232), arginine vasopressin (r=−0.236), plasma renin activity (r=0.092), or plasma aldosterone concentration (r=−0.058) when all subjects were analyzed together.

Discussion

By using a sensitive RIA for ET-1 with a detectable plasma level as low as 0.5 pg/ml, we could measure
Circulating ET-LI levels in peripheral venous plasma in all normal subjects and patients with hypertension or chronic renal failure that were studied. The mean concentrations of plasma ET-LI in normal subjects in our present and previous studies are comparable with those by sandwich enzyme immunoassay and RIA recently reported. Because of a marked reduction in renal blood flow induced by ET-1 (4×10^{-11}, 2×10^{-10} M) in the isolated perfused rat kidney, the possible role of ET-1 in the development of acute renal failure has been suggested. However, plasma ET-LI levels in patients with chronic renal failure (1.2×10^{-13} to 2.4×10^{-12} M) are far lower than those required to induce pharmacological actions thus far reported, including renal blood flow reduction in experimental animals.

The present study clearly shows that plasma ET-LI levels were significantly higher in all three hypertensive groups than those in comparable normotensive subjects; whereas other vasoactive hormones were not associated with hypertension. These data suggest that circulating ET-1 may be causally related to the development or maintenance of hypertension.

Recent preliminary studies have reported that plasma ET-LI levels were elevated in most of the hemodialyzed patients but undetectable in all normal subjects. Indeed, significantly elevated plasma ET-1 levels were observed in certain patients with chronic renal failure in the present study. However, plasma ET-1 levels do not correlate with residual renal function, which suggests that decreased glomerular filtration rate does not play an important role in the clearance of ET-1. Likewise, the difference in age of our normal group does not appear to contribute to the difference in plasma ET-1 levels. The apparent discrepancy between our results and those by other investigators may be accounted for by the heterogeneous populations of hypertensive or normotensive hemodialyzed patients studied or the different antibodies used in RIA. Full characterization of our antibody revealed that the principal antigenic determinant is directed toward C-terminal Trp^21, which is the residue essential for the biological activity of ET-1 and is shared by all three isopeptides (ET-1, ET-2, and ET-3) as recently elucidated by cDNA cloning of human genome.

References
9. Marumo F, Sakamoto H, Ando K, Ishigami T, Kawakami M: A highly sensitive radioimmunoassay of atrial natriuretic pep-


**KEY WORDS** • plasma endothelin levels • essential hypertension • chronic renal failure • hemodialysis • radioimmunoassay
Plasma endothelin levels in hypertension and chronic renal failure.
M Shichiri, Y Hirata, K Ando, T Emori, K Ohta, S Kimoto, M Ogura, A Inoue and F Marumo

Hypertension. 1990;15:493-496
doi: 10.1161/01.HYP.15.5.493

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1990 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/15/5/493

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/